Analysts are saying that Boston Scientific could rise by 2030. Bullish on BSX? Invest in Boston Scientific on SoFi with no commissions. If it’s your first time signing up for SoFi, you’ll receive up to $1,000 in stock when you first fund your account. Plus, get a 1% bonus if you transfer your investments and keep them there until December 31, 2025.
Demand for Boston Scientific Corp.’s (BSX) medical devices stands to increase as the nation ages. The company’s cardiovascular segment is the biggest contributor to revenue generation, while its medical surgery segment is growing at a fast rate. International growth has slowed, however, making Boston Scientific heavily reliant on the U.S. market
In this article, we’ll look at Wall Street sentiment, multiyear price forecasts, and the key factors that are playing a critical role in BSX’s path going forward.
Current Stock Overview
Market Cap: $146.66 billion
Trailing P/E Ratio: 57.27
Forward P/E Ratio: 28.49
1-Year Return: 16%
2025 YTD: 11%
BSX has a consensus Buy rating from 23 analysts, according to Benzinga. The average price target is $119.74 per share, which suggests a moderate upside from current levels. The highest price target is $140, and the lowest is $78. The three most recent ratings suggest a near-term average target of $131.67, suggesting a 33% upside.
Quick Snapshot Table of Predictions & Methodology for Forecasting
Year | Bullish Prediction | Average Prediction | Bearish Prediction |
|---|---|---|---|
2025 | $100.41 | $95.6 | $89.07 |
2026 | $109.63 | $96.83 | $82.57 |
2027 | $133.41 | $118.7 | $104.93 |
2028 | $210.64 | $176.16 | $133.61 |
2029 | $250.55 | $233.82 | $207.1 |
2030 | $241.84 | $230.78 | $218.4 |
2031 | $262.67 | $249.83 | $237.77 |
2032 | $329.34 | $299.81 | $263.13 |
2033 | $363.91 | $349.25 | $326.59 |
2040 | $738.54 | $673.91 | $592.35 |
2050 | $1821.17 | $1739.03 | $1644.64 |
The forecast range in this table is based on algorithmic projections provided by CoinCodex. These models use historical price trends, volatility patterns, and moving averages to estimate future stock prices over multiple time horizons.
Bull & Bear Case
Boston Scientific’s medical devices show strong demand in the U.S., but slowing global growth and high competition are meaningful challenges.
Bull Case
- Overall revenue growth is strong with forecasts for future gains as Boston Scientific launches new products
- An aging U.S. population should boost demand for the company’s products and services
- Boston Scientific’s Cardiovascular and MedSurg segments are both growing sales at a fast rate
Bear Case
- Boston Scientific’s revenue growth in Europe, the Middle East, and Africa has sharply decelerated, suggesting difficulties maintaining high growth rates outside of the U.S.
- BSX has a P/E ratio that is higher than 76% of companies in the medical devices and instruments industry, which may indicate that the stock is overvalued
- The medical devices space is highly competitive, which may make it harder for Boston Scientific to maintain appealing growth rates in the future
Stock Price Prediction for 2025
The average forecast from CoinCodex projects Boston Scientific losing value in 2025, and the highest projection sees little change. Decelerating revenue growth from international markets and competitors taking share in those regions may lead to declines.
Stock Price Prediction for 2026
CoinCodex’s average forecast sees BSX stock losing value through most of next year with an uptick expected toward the end. Any slowdown in U.S. sales could make it more difficult for the stock to maintain its high valuation. Any slowdown with Boston Scientific’s core cardiovascular business can also hurt the stock.
Stock Price Prediction for 2030
CoinCodex projects the stock rallying in 2030. An aging population may boost the company’s earnings as more patients turn to Boston Scientific for its cardiovascular and medical surgery services. Rising revenue and net income may also preserve BSX stock’s high P/E ratio and possibly warrant a higher valuation.
Investment Considerations
Boston Scientific has delivered impressive long-term returns for investors and has two high-growth segments that continue to drive the stock higher.
Decelerating sales growth in some international markets is concerning, but the company continues to perform well in the U.S. with strong revenue.
Investors who want a growth stock in the medtech industry may want to take a closer look at BSX.
About Marc Guberti
Marc Guberti is an investing writer passionate about helping people learn more about money management, investing and finance. He has more than 10 years of writing experience focused on finance and digital marketing. His work has been published in U.S. News & World Report, USA Today, InvestorPlace and other publications.
